Arbutus Biopharma Corp logo

Arbutus Biopharma Corp

ABUS | NASDAQ
Chart Builder DCF Calculator
$5
-$0.01 (-0.20%)
At close: Sep 21, 2026, 4:00 PM ET
$5.03
+$0.03 (+0.54%)
After-hours: Sep 21, 2026, 7:53 PM ET

Market Data

Market Cap
$989.66M
Enterprise Value
$898.69M
Beta
0.62
Average Volume
2.44M
Shares Outstanding (Diluted)
197.47M
Shares Change YoY
2.64%
Institutional Ownership
71.73%
Exchange
NASDAQ
ISIN
CA03879J1003

Price Performance

Price Change 1M
-3.9%
Price Change 3M
12.4%
Price Change 6M
10.4%
Price Change YTD
4.8%
Price Change 1Y
12.9%
Price Change 3Y
159.1%
Price Change 5Y
8.2%
1M CAGR (ann.)
10.3%
1Y CAGR (ann.)
13.1%
5Y CAGR (ann.)
2.7%
All-Time CAGR
-1.2%

Valuation

PE Ratio
6.41
Forward PE
N/A
PEG Ratio
0.01
Forward PEG
-0.06
PS Ratio
5.44
Forward PS
240.90
PB Ratio
3.82
P/FCF Ratio
-40.11
P/Adj. FCF Ratio
-32.78
P/OCF Ratio
-41.67
EV/Sales
4.95
EV/EBIT
5.87
EV/EBITDA
5.87
EV/FCF
-36.49
Earnings Yield
15.6%
FCF Yield
-2.5%
Adj. FCF Yield
-3.0%

Financial Health

Net Cash
$89.51M
Total Debt
$3.63M
Cash & Short-Term Investments
$92.63M
Total Assets
$274.03M
Current Ratio
81.42
Quick Ratio
81.42
Debt / Equity Ratio
0.01
Debt / EBITDA
0.02
Debt / FCF
-0.15
OCF / Debt
-6.79
Interest Coverage
1,937.05
Altman Z-Score
36.31
Piotroski F-Score
6

Margins & Profitability

Gross Profit Margin
100.0%
Operating Profit Margin
81.0%
EBITDA Margin
84.3%
Net Profit Margin
84.2%
FCF Margin
-13.6%
Adj. FCF Margin
-16.6%
SBC / Revenue
3.0%
SBC Impact (per share)
-22.4%

Returns

Return on Assets
55.9%
Return on Equity
91.0%
Return on Invested Capital
54.3%
Return on Capital Employed
54.4%
Return on Tangible Assets
55.9%

Historical Growth (CAGR)

Revenue CAGR 3Y
97.7%
Revenue CAGR 5Y
85.2%
Revenue CAGR 10Y
26.3%
EPS CAGR 3Y
3050.0%
EPS CAGR 5Y
146.5%
EPS CAGR 10Y
35.8%
FCF CAGR 3Y
46.0%
FCF CAGR 5Y
8.2%
FCF CAGR 10Y
2.9%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
10
EPS Growth Next 3Y
-24.5%
Revenue Growth Next 3Y
-1.5%
Earnings Date
Nov 15, 2026
EPS Estimate (next Q)
-$0.02
EPS Growth Est (next Q)
-42.0%
Revenue Est (next Q)
$1M
Revenue Growth Est (next Q)
89.0%

Fair Value Estimates

Graham Number
$4.79
Graham Upside
-4.2%
Lynch Fair Value
$19.50
Lynch Upside
290.0%
Price Target
$8.50
Price Target Upside
70.0%

Cash Flow

Operating Cash Flow
$-24.63M
Free Cash Flow
$-24.63M
Adj. Free Cash Flow
$-30.13M
FCF Per Share
-$0.12
OCF Per Share
-$0.12
OCF/S Ratio
-13.6%

Income Statement

Revenue
$181.72M
Gross Profit
$181.69M
Operating Income
$147.22M
EBITDA
$153.17M
Net Income
$153.05M
EPS (Diluted)
$0.78
Revenue / Employee
$9.56M
Profit / Employee
$8.06M
Employees
19

© 2026 bestshares.com. All rights reserved.